Protalix BioTherapeutics, Inc.: Form 10-K for the period ended Dec 31, 2025
Filed with the SEC on Mar 18, 2026 and accepted by EDGAR at Mar 18, 2026, 11:12 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2025-01-01 to 2025-12-31 | $52.7m | us-gaap:Revenues |
| Cost of revenue | 12 months2025-01-01 to 2025-12-31 | $27.0m | us-gaap:CostOfRevenue |
| Research and development | 12 months2025-01-01 to 2025-12-31 | $19.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2025-01-01 to 2025-12-31 | $11.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2025-01-01 to 2025-12-31 | −$5.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2025-01-01 to 2025-12-31 | $996.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2025-01-01 to 2025-12-31 | −$6.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2025-01-01 to 2025-12-31 | −$0.08 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2025-01-01 to 2025-12-31 | −$0.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2025-01-01 to 2025-12-31 | 78,546,234 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2025-01-01 to 2025-12-31 | −$12.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2025-01-01 to 2025-12-31 | $1.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-12-31 | $14.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-12-31 | $66.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-12-31 | $82.3m | us-gaap:Assets |
| Current liabilities | At period end2025-12-31 | $26.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-12-31 | $34.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-12-31 | $48.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-26-029858. Last ingested by Listed: Oct 24, 2026, 15:02 ET. Listed shows no prices and gives no investment advice.